BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38762572)

  • 1. Topographic analysis of pancreatic cancer by TMA and digital spatial profiling reveals biological complexity with potential therapeutic implications.
    Bingham V; Harewood L; McQuaid S; Craig SG; Revolta JF; Kim CS; Srivastava S; Quezada-Marín J; Humphries MP; Salto-Tellez M
    Sci Rep; 2024 May; 14(1):11361. PubMed ID: 38762572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
    Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
    J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer.
    Jiang S; Zhu L; Yang J; Hu L; Gu J; Xing X; Sun Y; Zhang Z
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):113-119. PubMed ID: 29050937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
    Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
    Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens.
    Rasmussen LG; Verbeke CS; Sørensen MD; Pfeiffer P; Tan Q; Mortensen MB; Fristrup C; Detlefsen S
    Pancreatology; 2021 Apr; 21(3):530-543. PubMed ID: 33637450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SWATH-MS based proteomic profiling of pancreatic ductal adenocarcinoma tumours reveals the interplay between the extracellular matrix and related intracellular pathways.
    Nweke EE; Naicker P; Aron S; Stoychev S; Devar J; Tabb DL; Omoshoro-Jones J; Smith M; Candy G
    PLoS One; 2020; 15(10):e0240453. PubMed ID: 33048956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
    Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRMT1 promotes pancreatic cancer growth and predicts poor prognosis.
    Song C; Chen T; He L; Ma N; Li JA; Rong YF; Fang Y; Liu M; Xie D; Lou W
    Cell Oncol (Dordr); 2020 Feb; 43(1):51-62. PubMed ID: 31520395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.
    Park JK; Jeong HO; Kim H; Choi JH; Lee EM; Kim S; Jang J; Choi DW; Lee SH; Kim KM; Jang KT; Lee KH; Lee KT; Lee MW; Lee JK; Lee S
    Mol Cancer; 2024 May; 23(1):87. PubMed ID: 38702773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma.
    Yang J; Lin P; Yang M; Liu W; Fu X; Liu D; Tao L; Huo Y; Zhang J; Hua R; Zhang Z; Li Y; Wang L; Xue J; Li H; Sun Y
    Genome Biol; 2021 Jan; 22(1):4. PubMed ID: 33397441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.
    Jandaghi P; Najafabadi HS; Bauer AS; Papadakis AI; Fassan M; Hall A; Monast A; von Knebel Doeberitz M; Neoptolemos JP; Costello E; Greenhalf W; Scarpa A; Sipos B; Auld D; Lathrop M; Park M; Büchler MW; Strobel O; Hackert T; Giese NA; Zogopoulos G; Sangwan V; Huang S; Riazalhosseini Y; Hoheisel JD
    Gastroenterology; 2016 Dec; 151(6):1218-1231. PubMed ID: 27578530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma.
    Iakovlev V; Siegel ER; Tsao MS; Haun RS
    Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1135-42. PubMed ID: 22573795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Expression and Survival Significance of Glucose Transporter-1 in Pancreatic Cancer: Meta-Analysis, Bioinformatics Analysis and Retrospective Study.
    Du J; Gu J; Deng J; Kong L; Guo Y; Jin C; Bao Y; Fu D; Li J
    Cancer Invest; 2021 Oct; 39(9):741-755. PubMed ID: 34229540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Pancreatic Cancer Biomarkers eIF1, eIF2D, eIF3C and eIF6 Play a Major Role in Translational Control in Ductal Adenocarcinoma.
    Golob-Schwarzl N; Puchas P; Gogg-Kamerer M; Weichert W; Göppert B; Haybaeck J
    Anticancer Res; 2020 Jun; 40(6):3109-3118. PubMed ID: 32487605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma.
    Yang G; Wang Y; Xiao J; Zhao F; Qiu J; Liu Y; Chen G; Cao Z; You L; Zheng L; Zhang T; Zhao Y
    Cell Oncol (Dordr); 2021 Apr; 44(2):345-355. PubMed ID: 33125631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma.
    Huang S; Li Y; Hu J; Li L; Liu Z; Guo H; Jiang B; Chen J; Li J; Xiang X; Deng J; Xiong J
    J Cell Mol Med; 2021 May; 25(9):4275-4286. PubMed ID: 33834618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.